The North America herpes simplex virus treatment market was valued at USD 605.44 Million in 2025, driven by increased funding to advance herpes simplex virus research in the region. The market is expected to grow at a CAGR of 7.50% during the forecast period of 2026-2035, reaching a value of USD 1247.83 Million by 2035.
Base Year
Historical Period
Forecast Period
In the United States, herpes simplex virus (HSV) 1 and 2 are considered the most common viral infections. This rising disease burden directly impacts the market demand for effective treatments.
Increased funding and initiatives to advance herpes simplex virus research are the major market trends.
The growing emphasis on the development of innovative treatments such as gene therapy to permanently cure this contagious viral infection is influencing the market share.
Compound Annual Growth Rate
7.5%
Value in USD Million
2026-2035
*this image is indicative*
Herpes simplex virus (HSV) or herpes is a treatable infection that can cause painful ulcers or blisters. Type 1 (HSV-1) and Type 2 (HSV-2) are two types of herpes simplex virus. Anti-HSV medications such as acyclovir, famciclovir, and valacyclovir, are generally prescribed to prevent the virus from multiplying. Oral pain relievers (paracetamol or ibuprofen) and topical pain relievers (benzocaine, L-lysine, and docosanol) are often taken to manage pain. Heightened patient awareness surrounding herpes is leading to higher diagnosis rates, which contributes to the expansion of the global herpes simplex virus treatment market. Further, the increasing focus on the development of innovative treatments such as gene therapy to permanently cure the infection is expected to drive the North America herpes simplex virus treatment market growth.
In the United States, herpes simplex virus (HSV) 1 and 2 are considered the most common viral infections. Around 80% of individuals between the ages of 14 and 49 are affected by HSV-1 and over 10% are infected with HSV-2. To date, there are no HSV vaccines approved by the US Food and Drug Administration and current treatment strategies are ineffective against latent HSV infections. To accelerate the development of vaccines, therapeutics, and diagnostics against herpes, the National Institutes of Health (NIH) established the Strategic Plan for Herpes Simplex Virus Research 2023-2028, aligning with the Sexually Transmitted Infections (STI) National Strategic Plan. The NIH HSV research plan states 4 priorities: increase knowledge of HSV biology, improve diagnosis, enhance treatment strategies, and advance research to prevent this viral infection. Such initiatives are likely to expedite the introduction of novel interventions, which will directly impact the North America herpes simplex virus treatment market demand.
One of the major market trends is the rising funding for herpes simplex virus research with the aim of reducing the associated health consequences. In October 2023, infectious disease company, Rational Vaccines, Inc. (RVx) announced that it had received USD 2.8 million in funding from the National Institute of Health (NIH) to boost its research in the treatment, diagnosis, and prevention of the herpes simplex virus infection. The company was awarded three separate grants to further its development of highly sensitive HSV-type-specific tests, live-attenuated HSV-1 strain ‘VC2’ to prevent and treat ocular herpes, and prophylactic and therapeutic HSV vaccines to curb the spread of herpes. Increased investment to stimulate advancements in herpes simplex virus testing and treatments is poised to augment the market share.
The EMR’s report titled “North America Herpes Simplex Virus Treatment Market Report and Forecast 2026-2035” offers a detailed analysis of the market based on the following segments:
Breakup by Type
Breakup by Drug Type
Breakup by Route of Administration
Breakup by Region
The key features of the market report include clinical trials analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
F. Hoffmann-La Roche AG, a global pioneer in pharmaceuticals and diagnostics, is actively involved in developing serology and molecular assays to provide testing and result interpretation of herpes simplex virus infections.
The global biopharmaceutical company AbbVie Inc. is involved in the clinical development of treatments intended for combating viral infections.
Johnson & Johnson Innovative Medicine is known for heavily investing in its research initiatives to develop therapeutics and vaccines for the treatment and prevention of life-threatening infectious diseases.
GlaxoSmithKline plc, a British multinational pharmaceutical company headquartered in London, is conducting a clinical trial to evaluate its targeted immunotherapy (GSK3943104A) efficacy against HSV infections.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other players in the market include Sanofi, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Merck & Co., Inc., and Pfizer Inc.
Upto 15% Off
USD
$2699 $2429
$4299 $3869
$5799 $4949
$6999 $5949
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about USD 605.44 Million in 2025 driven by the increasing research and development activities in the region.
The market is anticipated to grow at a CAGR of 7.50% during the forecast period of 2026-2035, likely to reach a market value of USD 1247.83 Million by 2035.
The rising prevalence of herpes simplex virus infections and increasing healthcare expenditure are fuelling the demand for the market.
One of the significant trends in the market is the increased funding for herpes simplex virus research. In October 2023, Rational Vaccines, Inc. (RVx) announced that it had received USD 2.8 million in funding from the National Institute of Health (NIH) to boost its research in the treatment, diagnosis, and prevention of the herpes simplex virus infection.
Based on the type, the market is segmented into herpes simplex virus-1 infection, and herpes simplex virus-2 infection, among others.
By drug type, the market is divided into Acyclovir, Valacyclovir, and Famciclovir, among others.
The market breakup by route of administration includes oral, parenteral, and topical.
The market segmentation by countries includes the United States and Canada.
The key players in the market are Roche Holding AG, AbbVie Inc., Johnson & Johnson, GlaxoSmithKline plc, Sanofi, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Merck & Co., Inc., and Pfizer Inc.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Drug Type |
|
| Breakup by Route of Administration |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share